Showing 21 - 30 of 214
Across the world, the SARS-CoV-2 (COVID-19) pandemic has disproportionately affected economically disadvantaged groups. This differential impact has numerous possible explanations, each with significantly different policy implications. We examine, for the first time in a low- or middle-income...
Persistent link: https://www.econbiz.de/10013228479
Persistent link: https://www.econbiz.de/10014531526
Persistent link: https://www.econbiz.de/10010337106
Persistent link: https://www.econbiz.de/10002004250
Persistent link: https://www.econbiz.de/10001673206
Persistent link: https://www.econbiz.de/10001773512
Persistent link: https://www.econbiz.de/10011853442
We determine the optimal health policy mix when the average utility of patients increases with the supply of drugs available in a therapeutic class. Health risk coverage rely on two instruments, copayment and reference pricing, that affect the supported risk composed by health expenses and...
Persistent link: https://www.econbiz.de/10010291663
This article examines a model of competition between two types of health insurer: Health Maintenance Organizations (HMOs) and nonintegrated insurers. HMOs vertically integrate health care providers and pay them at a competitive price, while nonintegrated health insurers work as indemnity plans...
Persistent link: https://www.econbiz.de/10011599861
We compare two genetic testing regulations, Disclosure Duty (DD) and Consent Law (CL), in an environment where individuals choose to take a genetic test or not. DD forces agents to reveal the test results to their insurers, resulting in a discrimination risk. CL allows agents to withhold that...
Persistent link: https://www.econbiz.de/10011657123